Nut Consumption and Prevention of Non-communicable Diseases: A Global Individual Participant Data Meta-analysis
NCT07205978
Alzheimer Disease, Basal Ganglia Diseases
Copenhagen, Denmark
View Trial DetailsNCT Number: NCT06814431
This multicenter retrospective observational study investigates the incidence of malignant neoplasms in Parkinson's disease (PD) patients carrying heterozygous pathogenic variants in the GBA1 gene. The study compares these patients to individuals with idiopathic PD and to the general population within a large national cohort.
The rationale for the study lies in the growing evidence indicating an increased risk of malignant neoplasms in patients affected by Gaucher disease.
The primary objective is to assess whether PD patients with GBA1 mutations have a higher incidence of malignant neoplasms compared to the general population. Secondary objectives include comparing the incidence of malignant neoplasms between GBA1-PD and idiopathic PD patients, as well as between idiopathic PD patients and the general population. Additionally, the study aims to characterize oncological conditions by sex, age, center, and tumor site, with specific attention to distinguishing hematologic tumors from solid tumors.
By identifying potential associations between GBA1 mutations and malignancies in PD, the findings could guide more comprehensive patient management, including screening for malignant neoplasms alongside Parkinson's disease care.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Ospedale A. Perrino, Brindisi, Italy
The study will involve a network composed by different Italian Movement Disorders Centres and the corresponding local cancer registries, responsible for the active collection of cancer cases. Data will be collected from approximately 3000 consecutive Parkinson's disease (PD) patients, including about 500 patients carrying GBA1 mutations and 2500 idiopathic PD. Data about the presence of malignancies will be extracted from the Local Cancer Registries for each patient.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From birth to a maximum of 36 months after enrollment
The incidence of malignant neoplasms in Parkinson's disease (PD) patients carrying the GBA1 mutation (GBA1-PD) will be calculated and compared to that of the general population to assess any potential increase in risk.
Time frame: From birth to a maximum of 36 months after enrollment
The incidence of malignant neoplasms in Parkinson's disease (PD) patients carrying the GBA1 mutation (GBA1-PD) will be compared to that of idiopathic PD patients using a Chi-Square test to evaluate statistical significance
Time frame: From birth to a maximum of 36 months after enrollment
The incidence of neoplasms in patients with idiopathic Parkinson's disease (PD) will be compared to that of the general population.
Time frame: From birth to a maximum of 36 months after enrollment
Logistic regression analysis will be conducted to evaluate the association between neoplasms and PD subgroups (GBA1 and idiopathic PD), accounting for clinical and demographic covariates.
Contact information is provided by the study sponsor or research team.
Azienda USL Reggio Emilia - IRCCS
Other Gov
Acronym: ONCOGBA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07205978
Alzheimer Disease, Basal Ganglia Diseases
Copenhagen, Denmark
View Trial DetailsNCT06583395
Adnexal Diseases, Amyotrophic Lateral Sclerosis
Palm Desert, California, United States
View Trial DetailsNCT06416267
Alzheimer Disease, Autoimmune Diseases
View Trial DetailsNCT03847753
Acquired Immunodeficiency Syndrome, Allergy
View Trial Details